GlassScriptPhysician profile
Kara Dutko
NPI 1841976966
$6,638.83
in general payments reported to CMS, 2019-2025
28 companies · $3,490 in 2025
The $3,490 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $73.42 · 2024: $3,075 · 2025: $3,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,480 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,479.84 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,254.25 | 2023-2025 | Evenity, Otezla, Krystexxa |
| Abbvie INC. | $958.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $736.45 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $499.77 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $469.40 | 2024-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $389.59 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $344.74 | 2024-2025 | |
| Radius Health, INC. | $208.96 | 2024-2025 | Tymlos |
| Pfizer INC. | $178.59 | 2024-2025 | |
| Glaxosmithkline, LLC. | $174.60 | 2024-2025 | Nucala, Benlysta |
| Lilly USA, LLC | $171.44 | 2023-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $163.21 | 2024-2025 | Orencia |
| Kyowa Kirin, INC. | $145.53 | 2024-2025 | Crysvita |
| Organon LLC | $132.55 | 2024-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.52 | 2024-2025 | Cyltezo, Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $107.66 | 2025 | Acthar |
| Genentech USA, INC. | $104.37 | 2024-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $97.46 | 2024-2025 | Strensiq |
| Sandoz INC. | $71.51 | 2024-2025 | Hyrimoz |
| Invivyd INC | $70.96 | 2025 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $41.96 | 2024 | Horizant |
| Almatica Pharma LLC | $41.71 | 2025 | Teriparatide |
| Fresenius Kabi USA, LLC | $40.45 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $35.77 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.95 | 2023 | Arcalyst |
| Sobi, INC | $21.68 | 2025 | |
| Genzyme Corporation | $20.49 | 2024 | |
| Tonix Medicines, INC. | $16.20 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Dutko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.